For 45 people with localized scleroderma, six months of treatment with dupilumab brought better results than a placebo, while also reducing skin inflammation and activity in genes linked to scarring. The findings come from a clinical trial in Cologne and offer an early sign that blocking two immune signals could help slow the tissue hardening known as fibrosis.

Fibrosis happens when connective tissue grows abnormally stiff, making it harder for affected tissue to work. It can develop in many parts of the body, and the risk rises with age. Yet only a few medicines are approved for fibrotic diseases. Localized scleroderma affects the skin, making it a useful condition in which to test whether a suspected driver of fibrosis can be safely and effectively targeted in people.

The research team, led by Dr. Sabine Eming, professor of dermatology at the University of Cologne, studied signals called interleukin-4 and interleukin-13, or IL-4 and IL-13. Earlier laboratory research had pointed to both as important in fibrosis. In the new randomized, placebo-controlled phase II study, the team tested dupilumab, a drug that blocks the signals’ shared pathway. The medicine is already used to reduce inflammation in conditions including neurodermatitis and asthma.

Over six months, researchers tracked changes in disease severity, inflammation and gene activity. Participants receiving dupilumab showed marked clinical improvement compared with those given a placebo. Their local inflammation fell, and genes associated with fibrosis were suppressed. The results suggest that IL-4 and IL-13 signaling helps drive the inflammatory process that can lead to skin fibrosis, and that interrupting this pathway may improve the disease’s course.

The trial is an early proof-of-concept study: its purpose is to see whether a treatment works as intended and whether the initial results justify larger tests. Its 45 participants and six-month duration mean it cannot settle how well dupilumab works over the long term, or establish its safety and effectiveness for other fibrotic conditions. Still, the findings offer a clear direction for further research, especially because fibrosis can affect many organs and treatment options remain limited.

Eming said the findings are promising for the possible prevention of other fibrotic diseases. She and her colleagues say larger studies with longer treatment periods are needed to confirm dupilumab’s effectiveness and safety in localized scleroderma. Published in Annals of the Rheumatic Diseases in 2026, the study provides human evidence that blocking IL-4 and IL-13 may do more than ease inflammation: it may also help keep the biological processes linked to tissue hardening in check.